GENENTECH’S FENEBRUTINIB IS THE FIRST BTK INHIBITOR TO RECEIVE U.S. FDA FILING ACCEPTANCE IN BOTH RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

Reuters · 3d ago

Please log in to view news